Ambros' $125m for pain disorder drug, and other financings
Our latest crop of biofinancings has nine-figure rounds for Ambros, Atavistik, Orum, and Addition, with Link Cell and Aeovian also raising new funds.
J&J's subcutaneous Rybrevant cleared by FDA
J&J has claimed FDA approval for Rybrevant Faspro, a subcutaneous version of the lung cancer therapy central to its blockbuster hopes for the drug.
AI for the planet, AI for life sciences – with Patrick Leung
Patrick Leung – chief technology officer at Faro Health – discusses how AI can transform clinical trials.
Cracking the code: How European biotechs can win in the US m...
At Frontiers Health 2025, Mike Ryan, General Manager Europe at EVERSANA, tackled one of the most pressing questions for emerging pharma and biotech...
Latest News
Views & Analysis
Deep Dive
White Papers & Webinar
Podcasts & Video
Partner Content
5th mRNA-Based Therapeutics Summit Europe
The Summit is the leading European industry-focused forum dedicated to accelerating the development of messenger RNA (mRNA) medicines
VuuAI and Amiculum partner to transform content engagement i...
Amiculum, a global health communications agency, has entered into an exciting strategic collaboration with VuuAI, a GenAI-driven content production automation plat
10th Tumor Models Summit San Francisco
Join the West Coast's premier pharma and biotech gathering, the 10th Tumor Models Summit San Francisco, where innovation meets opportunity
The PM Society Careers Event – 18th February 2026
Join us for our popular event to see how your skills and interests could add value to this vital and constantly evolving industry.
Frontiers Health Turns 10
Celebrating a Decade of Innovation and Collaboration in Berlin, November 11–12, 2025 Berlin / November 7th, 2025 | Marking its 10th anniversary,
